BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 16104903)

  • 21. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
    Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
    Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
    Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
    BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Internal validation of an artificial neural network for prostate biopsy outcome.
    Stephan C; Cammann H; Bender M; Miller K; Lein M; Jung K; Meyer HA
    Int J Urol; 2010 Jan; 17(1):62-8. PubMed ID: 19925616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
    Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
    J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
    Pelzer AE; Volgger H; Bektic J; Berger AP; Rehder P; Bartsch G; Horninger W
    BJU Int; 2005 Nov; 96(7):995-8. PubMed ID: 16225515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
    Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The application of complexed PSA and its relative indexes in the diagnosis of prostate cancer].
    Chen ZH; Zhao J; Wu JM; Xiao CG
    Zhonghua Nan Ke Xue; 2003 Feb; 9(1):36-9. PubMed ID: 12680329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network.
    Stephan C; Meyer HA; Cammann H; Nakamura T; Diamandis EP; Jung K
    Biol Chem; 2006 Jun; 387(6):801-5. PubMed ID: 16800743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.